ArticleRadiation oncology (London, England)2012
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Article in Radiation oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.Medicine · 2021Pooled it
- Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.World journal of surgical oncology · 2017Pooled it
- Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer.Radiation oncology (London, England) · 2015Trial
- Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2013Trial
- Article
- Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approachesAnnals of hepato-biliary-pancreatic surgery · 2022Article
- Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection.Frontiers in oncology · 2022Article
- Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma.World journal of gastrointestinal surgery · 2021Review
- Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report.Surgical case reports · 2020Article
- Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?Therapeutic advances in medical oncology · 2020Review
- Article
- Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation.Cancers · 2019Article
- Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma.Radiation oncology journal · 2018Article
- Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Review
- Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?Radiation oncology (London, England) · 2017Review
- Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.Molecular and clinical oncology · 2017Article
- Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma.International journal of surgery. Oncology · 2017Article
- Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.Journal of gastrointestinal oncology · 2017Article
- Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines.Frontiers in oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate efficacy and secondary resectability in patients with locally advanced pancreatic cancer (LAPC) treated with neoadjuvant chemoradiotherapy (CRT). PATIENTS AND
methodsA total of 215 patients with locally advanced pancreatic cancer were treated with chemoradiation at a single institution. Radiotherapy was delivered with a median dose of 52.2 Gy in single fractions of 1.8 Gy. Chemotherapy was applied concomitantly as gemcitabine (GEM) at a dose of 300 mg/m2 weekly, followed by adjuvant cycles of full-dose GEM (1000 mg/m2). After neoadjuvant CRT restaging was done to evaluate secondary resectability. Overall and disease-free survival were calculated and prognostic factors were estimated.
resultsAfter CRT a total of 26% of all patients with primary unresectable LAPC were chosen to undergo secondary resection. Tumour free resection margins could be achieved in 39.2% (R0-resection), R1-resections were seen in 41.2%, residual macroscopic tumour in 11.8% (R2) and in 7.8% resection were classified as Rx. Patients with complete resection after CRT showed a significantly increased median overall survival (OS) with 22.1 compared to 11.9 months in non-resected patients. Median OS and disease-free survival (DFS) of all patients were 12.3 and 8.1 months respectively. In most cases the first site of disease progression was systemic with hepatic (52%) and peritoneal (36%) metastases. DISCUSSION: A high percentage of patients with locally advanced pancreatic cancer can undergo secondary resection after gemcitabine-based chemoradiation and has a relative long-term prognosis after complete resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.